The inhibitory effect of anti-allergic agent suplatast tosilate (IPD- 1151T) on methacholine- and allergen-induced bronchoconstriction in sensitized mice

Mediators of Inflammation

Volumn 9, Issue 2, 2000, Pages 77-84

  Asano, Kazuhito ^a   Mizutani, Tetsuya ^a   Shimane, Toshikazu ^a   Hisano, Masataka ^a   Hisamitsu, Tadashi ^a   Suzaki, Harumi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Allergen; Anti allergic agent; Bronchoconstriction; IgE; IL 4; IPD 1151T; Methacholine; Mouse; Suppression

Indexed keywords

ALLERGEN; HEMOCYANIN; IMMUNOGLOBULIN E; INTERLEUKIN 4; METHACHOLINE; SUPLATAST TOSYLATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; ASTHMA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; DRUG STRUCTURE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; BRONCHUS;

EID: 0033927413     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/096293500411532     Document Type: Article

References (33)

1. 1. Hargreave FE, Ryan G, Thomson NC et al. Bronchial responsiveness to histaminc or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol 1981: 68:347-55
2. 2. Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine relationship to minimum treatment to control symptoms of asthma. Thorax 1981: 36:575-9
3. 3. Barnes PJ. A new approach to the treatment of asthma. New Engl Med 1989: 321:1517-27
4. 4. Gorski P, Kolacinska B, Wittczak T. Analysis of the clinical state of patients with occupational asthma following cessation of exposure to allergens. Occup Med (Lond) 1999: 49:285-9
5. 5. Renz H, Smith HR, Honson JE, Ray BS, Irvin CG, Gelfand EW. Aerosolized antigen exposure without adjuvant causes increased IgE production and increased airway responsiveness in the mouse. J Allergy Clin Immunol 1992: 89:1127-38
6. 6. Larsen GL, Renz H, Loader JE, Bradley KL, Gelfand EW Airway response to electrical field stimulation in sensitized inbred mice. Passive transfer of increased responsiveness with peribronchial lymph nodes. J Clin Invest 1992: 89:747-52
7. 7. Rabe KF, Watson N, Dent G et al. Inhibition of human airway sensitization by a novel monoclonal anti-IgE antibody, 17-9. Am J Respir Crit Care Med 1998: 157:1429-35
8. 8. Dobashi K, Iizuka K, Houjou S et al. Effect of cetirizine on antigen-induced tracheal contraction of passively sensitized guinea pigs. Ann Allergy Asthma Immunol 1996: 77:310-8
9. 9. Ring J, Bieber T, Vieluf D, Kunz B, Przybilla B. Atopic eczema, langerhans cells and allergy. Int Arch Allergy Appl Immunol 1991: 94:194-201
10. 10. Ra C, Kuromitsu S, Hirose T et al. Soluble human high-affinity receptor for IgE abrogates the IgE-mediated allergic reaction. Int Immunol 1993: 5:47-54
11. 11. Tunon de Lara JM, Okayama Y, Savineau JP, Marthan R. IgE-induccd passive sensitization of human isolated bronchi and lung mast cells. Eur Respir J 1995: 8:1861-5
12. 12. Ormstad H, Gaarder PI, Johansen BV, Lovik M. Airborne house dust elicits a local lymph node reaction and has an adjuvant effect on specific IgE production in the mouse. Toxicology 1998: 129:227-36
13. 13. Koda A, Yanagihara Y, Matsuura N. IPD-1151T: a prototype drug for IgE antibody synthesis modulation Agents Actions 1991: 34:369-78
14. 14. Matsuura N, Mori H, Nagai H, Koda A. Effect of suplatast tosilatc (IPD-1151T) on antibody formations in mice. Folia Pharm Japon [English text] 1992: 100:485-93
15. 15. Matsuura H, Mori H, Nagai H, Koda A. Effect of suplatast tosilate (IPD-1151T) on type I-IV allergic reactions. Folia Pharm Japon [English text] 1992: 100:495-501
16. 16. Konno S, Adachi M, Asano K et al. Supprcssive effects of IPD-1151T (suplatast tosilate) on induction of mast cells from normal mouse splenocytes. Eur J Pharmacol 1994: 259:15-20
17. 17. Iijima H, Tamura G, Hsiue TZ, Lin Y, Taniguchi H, Shirato K. Suplatast tosilate inhibits late response and airway inflammation in sensitized guinea pig. Am J Respir Crit Care Med 1999: 160:331-5
18. 18. Oda N, Minoguchi K, Yokoe T et al. Effect of suplatast tosilate (IPD-1151T) on cytikine production by allergen-specific human Th1 aand Th2 cell lines. Life Scie 1999: 65:763-70
19. 19. Kimata H. Selective enhancement of production of IgE. IgG4 and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol 1999: 82:293-5
20. 20. Tsukagoshi H, Nagashima M, Horie T et al. Kimura's disease associated with bronchial asthma presenting eosinophilia and hyperimmunoglobulinemia E which were attenuated by suplatast tosilate (IPD-1151T). Intern Med 1998: 37:1064-7
21. 21. Lee WY, Schon AH. Suppression of reaginic antibody formation. III. Relationship between immunogenicity and tolerogenicity of hapten-carrier conjugate. J Immunol 1976: 116:1711-8
22. 22. Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M. Anti-asthmatic activity of macrolide antibiotic, roxithromycin analysis of the possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 1994: 105:308-16
23. 23. Burden DT, Parkes MW. Effect of β-adorenoccptive blocking agents on the response to bronchoconstrictor drugs in the guinea-pig air overflow preparation Br J Pharmacol 1971: 41:122-31
24. 24. Martin TR, Gerard NP, Galli SJ, Drazen M. Pulmonary responses to bronchoconstrictor agonists in the mouse. J Appl Physiol 1988: 64:2318-23
25. 25. Behrens BL, Clark RAF, Marsh W, Larsen GL. Modulation of the late asthmatic response by antigen-specific immunoglobulin G in an animal model Am Rev Respir Dis 1984. 130:1134-9
26. 26. Marsh WR, Irvin CG, Murphy KR, Behrens BL, Larsen GL. Increases in airway reactivity to histamine and inflammatory cells in bronchoalveolar lavage after the late asthmatic response in an animal model. Am Rev Respir Dis 1985: 131:875-9
27. 27. Murphy KR, Wilson MC, Irvin CG, et al. The requirement for polymorphonuclcar leukocytes in the late asthmatic response and heightened airways reactivity in an animal model. Am Rev Respir Dis 1986: 134:62-8
28. 28. Tung R, Lichitenstein LM. In vitro histamine release from basophils of asthmatic and atopic individuals in D2O. J Immunol 1982: 128:2067-72
29. 29. MacDonald SM, Lichitenstein LM, Proud D et al. Studies of IgE-dependent histamine releasing factor: heterogeneity of IgE. J Immunol 1987: 139:506-12
30. 30. MacGlashan DW, Peters SP, Warner J, Lichitenstein LM. Characterization of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol 1986: 136:2231-9
31. 31 Murray JJ, Tonnel AB, Brash AR et al. Release of prostaglandin D2 into human airways during acute antigen challenge. New Eng J Med 1986: 315:800-4
32. 32. Tanaka DT, Grunstein MM. Effect of substance P on neurally mediated contraction of rabbit airway smooth muscle. J Appl Physiol 1986: 60:458-63
33. 33. Bethel RA, Curtis SP, Lien DC et al. Effect of PAF on parasympathetic contraction of canine airways. J Appl Physiol 1989: 66:2629-34